Navigation Links
Royalty Pharma Statement Regarding Elan Proposal
Date:3/6/2013

o in Royalty Pharma's Proposal;

 "Prothena"

Prothena Corporation plc;

 "SEC"

Securities and Exchange Commission;

 "Specialty Pharma

Companies"

Alkermes plc, Allergan, Inc., Cubist Pharmaceuticals, Inc., Endo Health Solutions 

Inc., Forest Laboratories, Inc., Jazz Pharmaceuticals plc, The Medicines Company,

Salix Pharmaceuticals, Ltd., Shire plc, Valeant Pharmaceuticals International, Inc. and Warner

Chilcott Plc;

 "Tysabri Conference Call"

the February 6, 2013 conference call following the announcement of the Tysabri Transaction;

 "Tysabri Consideration"

the consideration of US$3.249 billion payable by Biogen to Elan Group upon the completion of

the Tysabri Transaction;

 "Tysabri Royalty"

the royalty on Tysabri payable by Biogen to members of the Elan Group following the completion

of the Tysabri Transaction;

 "Tysabri Transaction"

the transaction between Elan and Biogen in relation to the restructuring of Elan's Tysabri collaboration with Biogen which was announced by Elan on February 6, 2013; and

 "Valeant"

Valeant Pharmaceuticals International, Inc. 

APPENDIX II: Chronology of EventsThe following chronology of recent events is provided as further background to the Proposal.

  • September 2011: Sale of Elan Drug Technologies (EDT) to Alkermes plc.
  • Summer 2012: Post-bapineuzumab clinical failure and announcement of spin-off of Prothena, Royalty Pharma developed an interest in Elan and Tysabri.
  • October to December 2012: Royalty Pharma had in-person meeting and several subsequent communications with Elan discussing ways in which Elan and Royalty Pharma might be able to work together, including Royalty Pharma's interest in potentially acquiring Elan.
  • 6 February 2013: Biogen and Elan announced Tysabri Transact
    '/>"/>

    • SOURCE RP Management, LLC
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

    Related biology technology :

    1. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
    2. Cowen Healthcare Royalty Partners Raises $1 Billion
    3. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
    4. Radiopharmaceuticals Market - Global Industry Analysis, Size, Share, Trends And Forecast, 2012 - 2018: MarketResearchReports.Biz
    5. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
    6. AVANIR Pharmaceuticals To participate in two conferences in March
    7. Favorable Scenario for Japan Pharma Industry in Coming Years, New Report Says
    8. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
    9. Technical Analysis on VIVUS and Achillion Pharma: Highlights on These Biotech Companies
    10. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
    11. Serialization in Pharmaceuticals, a Webinar Presented by Xtalks
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
    (Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
    (Date:5/21/2013)... Bed bugs have become so widespread in the ... turn to chemical-based pesticides for help to completely get rid ... those solutions present, the company advised the public to ... , According to My Cleaning Products, chemical-based pesticides are not ... It shared that the pests have already developed immunity to ...
    (Date:5/21/2013)... (PRWEB) May 21, 2013 Inflamax ... of the ITN to design the study, which ... two key clinical models used in the study ... and Nasal Allergen Challenge (NAC) models. Although both ... numerous publications, to date no direct comparison between ...
    Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
    ... Importance of Allergy Testing in Managing Chronic ... ... Phadia US Inc. announced today,that The National Asthma Education and Prevention ... for the Diagnosis and,Management of Asthma. Information in the guidelines reported ...
    ... steps ... towards public reporting status., SAN ANTONIO, Aug. 30 ... targeted cancer therapies with improved efficacy and reduced toxicity,announced the ... a control position in a public reporting shell company. ...
    ... Aug. 30 Pressure,BioSciences, Inc. (Nasdaq: ... has been,issued its first patent by the ... Biomolecular Complexes" (Number,2,259,318), this issuance extends the ... patents previously issued in the United States,Japan, ...
    Cached Biology Technology:Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management 2OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company 2Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
    (Date:5/21/2013)... is an uphill battle? Try staying fit in space, ... muscle and bone. , That,s the challenge a group ... new three-year, $1.2 million grant from NASA. Their goal ... exploratory missions. , "You could give astronauts the best ... them to stick to it, it isn,t going to ...
    (Date:5/21/2013)... Royal Philips Electronics (NYSE: PHG, AEX: PHIA) ... ultrasound with Philips, industry leading Live 3D TEE, now ... with available Live 3D TEE and ICE will be ... EuroPCR, official meeting for the European Association of Percutaneous ... launch in 2012, Philips CX50 xMATRIX has been the ...
    (Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
    Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
    ... Kimmel Award for Innovative Investigation on Monday, Nov. 5 at ... grant of a million dollars over five years. Taking ... the impulses that drive evolution. Living cells are, from this ... have all sorts of interesting consequences for many other molecules ...
    ... all" when it comes to weight loss through exercise, says ... Neil King, from QUT,s Institute of Health and Biomedical Innovation, ... with the University of Leeds in the UK, which has ... of Obesity. "When it comes to losing weight, a ...
    ... issue of BioScience describes the history and summarizes the ... surface and substrate. , Although more expensive to construct ... energy costs during a buildings lifetime and control storm-water ... structures are currently less common in the United States ...
    Cached Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Weight loss -- not one size fits all 2
    Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
    sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
    Recombinant Mouse MMP-9, CF...
    Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
    Biology Products: